share_log

Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study

Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study

從賽諾菲獲得的宏碁治療產品在更年期研究中失敗
Benzinga ·  2023/03/17 23:38
  • Acer Therapeutics Inc (NASDAQ:ACER) announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.
  • The study showed that ACER-801 was safe and well-tolerated but did not achieve statistical significance when evaluating ACER-801's ability to decrease the frequency or severity of hot flashes in postmenopausal women.
  • Related: Acer Therapeutics Expands ACER-801 Development Into Post-Traumatic Stress Disorder.
  • Hence, Acer is pausing the ACER-801 program until Acer has thoroughly reviewed the full data set.
  • Acer is continuing to focus on preparation for its commercial launch of OLPRUVA (sodium phenylbutyrate) for urea cycle disorders and the ongoing Phase 3 trial of EDSIVO (celiprolol) for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, subject to availability of additional capital beyond early in Q2 2023.
  • In December 2018, Acer entered into an exclusive license agreement with Sanofi SA (NASDAQ:SNY) to acquire worldwide rights to ACER-801 (osanetant).
  • Price Action: ACER shares are down 39.96% at $0.9306 on the last check Friday.
  • 宏碁治療 (NASDAQ: ACER) 宣布了其 2a 期概念驗證臨床試驗中的頂線結果，以評估 ACER-801（氧化汀）作為治療與更年期相關的中度至重度血管運動症狀（VMS）的潛在治療方法。
  • 該研究表明，ACER-801 安全且耐受性良好，但在評估 ACER-801 降低絕經後婦女潮熱的頻率或嚴重程度的能力時，沒有達到統計意義。
  • 相關： 宏碁治療將 ACER-801 的發展擴展到創傷後應激障礙。
  • 因此，宏碁正在暫停 ACER-801 程序，直到宏碁已經徹底審查了完整的數據集。
  • 宏碁將繼續專注於商業推出 OLPRUVA（苯基丁酸鈉）用於尿素循環障礙的準備工作，以及正在進行的 EDSIVO（西里洛爾）3 期試驗用於血管艾勒斯-丹洛斯綜合症患者的第三期試驗，但需在 2023 年第二季度之後的額外資本可用。
  • 於 2018 年 12 月，宏碁與合作簽訂獨家授權協議 賽諾菲 (納斯達克:SNY) 獲得對 ACER-801 的全球權利 (阿桑奈特).
  • 價格行動： 上週五，宏碁股票下跌 39.96%，報 0.9306 美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論